Study of Cellutome System for Treatment of Individual Lesions in EB Pts

Inclusion Criteria

• •Patient (Recipient)
• •Diagnosis of Dystrophic Epidermolysis Bullosa (DEB) or Junctional Epidermolysis Bullosa (JEB) with at least one wound, visibly free from infection (or previously treated) and meets the eligibility for Arm A or Arm B based on the skin graft source:
• •Cell harvest from previous hematopoietic cell transplantation (HCT) donor (Arm A) - not applicable if Arm B
• •* At least 6 months after hematopoietic cell transplantation with donor chimerism
• •* Peripheral blood donor chimerism should be measured within 21 days of grafting and be \>/= 5% and stable. Stability of chimerism will be determined by the protocol team and based on 3 peripheral blood chimerism values at least 1 month apart.
• •* No history of pre-BMT autoimmune cytopenias
• •* Off immune suppressive therapy
• •* Original transplant donor is available and willing to be the epidermis donor
• •Self-donation (Arm B) - not applicable if Arm A
• •* Proven somatic reversion
• •* Site for skin grafting free of cellulitis and any other clinically evident abnormalities
• •* Meets donor eligibility
• •Insurance pre-authorization for procedure, if applicable
• •Voluntary written consent (patient or parent/guardian for minors with assent) prior to any research related procedures or treatment.
• •Skin Graft Donor (either hematopoietic cell transplantation donor for the EB patient \[Arm A\] or EB patient herself/himself \[Arm B\])
• •Age \> 2 years (based on prior safety testing of the device)
• •Healthy on physical examination in the opinion of the evaluating provider
• •Negativity for Hepatitis B and C, HIV, and HTLV1/2 within 30 days of donation
• •Voluntary written consent (donor or parent/guardian for minors with assent) prior to any research related procedures